<DOC>
	<DOCNO>NCT00961909</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass efficacy , safety , tolerability , pharmacokinetics pharmacodynamics RO5095932 patient type 2 diabetes mellitus . Patients randomize receive either RO5095932 subcutaneously weekly placebo 4 week ( part 1 ) 6 week ( part 2 ) , addition current stable dos metformin .</brief_summary>
	<brief_title>A Study RO5095932 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patient , 1865 year age females either surgically sterile postmenopausal type 2 diabetes treat stable dose metformin BMI 2539kg/m2 HbA1c 7 10 % fast plasma glucose 7 13.3mmol/L history clinically significant cardiovascular disease history clinically significant hepatic renal disease impairment recent therapy insulin , thiazolidinedione , glucagonlike peptide1 analogue , amylin analogue and/or DPPIV inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>